Acne Phase 2 - Probability of Success and Likely Market Response, page-38

BOTANIX are at least two years ahead of any would be competitors they have an exhaustive and formidable amount of real estate in the Intellectual Property surrounding Synthetic CBD and the Optimum % of dose. They are literally pulling the ladder up behind themselves..
It would be incredibly difficult to try and pick a path through BOT IP to even come close... Matt and the team are incredibly focused and understand market protection is what the Mega Pharmas require.....
Personally thought the SP would have stepped up to 30c and above ,,, seems the wider market is poised awaiting further results....
Most investors in BOT are early adopters of tech, they have seen in the splinter of their minds eye the product working and on the shelves... early adopters of technology make up circa 5% of the investment Sector..... on the next set of results the other 95% come in ,,,,,,,